DUBLIN--(BUSINESS WIRE)--The "Global Compounding Pharmacy Market 2018-2022" report has been added to ResearchAndMarkets.com's offering.
The global compounding pharmacy market will earn a revenue of about USD 12 billion by 2022.
The report has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
One trend in the market is increasing prevalence of hormonal imbalance. Factors such as growing geriatric population, unhealthy eating habits of people, consumption of medications, stress, and increasing prevalence of thyroid, diabetes, and tumors, are driving the rising incidences of hormonal imbalance. This also results in physical and mental issues.
According to the report, one driver in the market is increase in healthcare and pharmaceutical spending. Proportionally, pharmaceutical spending is also increasing due to the increasing demand for medications. The growing incidences of chronic diseases are encouraging the consumers to visit compounding pharmacies.
Further, the report states that one challenge in the market is non-availability of insurance. Health insurance plans do not cover compounded drugs. Hence, people must spend out-of-pocket to purchase compounded medications. This is a challenge for people from low-income groups.
Key Vendors
- Fagron
- B. Braun Melsungen
- Fresenius
- Wedgewood Pharmacy
- Dougherty's Pharmacy
- Village Compounding Pharmacy
Key Topics Covered
1. Executive Summary
2. Scope of the Report
3. Research Methodology
4. Market Landscape
5. Market Sizing
6. Five Forces Analysis
7. Segmentation by Product
8. Customer Landscape
9. Regional Landscape
10. Decision Framework
11. Drivers and Challenges
12. Market Trends
13. Vendor Landscape
14. Vendor Analysis
For more information about this report visit https://www.researchandmarkets.com/research/6jvzv6/global?w=4
